瑞士百達集團
Championing Health Innovation
Society · 2023年02月15日
0 min read
Will humankind be able to detect cancers long before they affect one's health? From telemedicine to wearable devices, and artificial intelligence to genomics, the health innovation space is buzzing with exciting developments that promise to improve outcomes and quality of life across the globe.
Listen to our latest Found in Conversation episode ‘Championing Health Innovation’ as we explore the future of medicine and delve into the latest advancements, technologies and investment opportunities shaping the biotech and health industries. Joining are Sangeeta N.Bhatia, MIT's medical engineering professor and biotech entrepreneur, Lydia Haueter Senior Investment Manager at Pictet Asset Management, and David Braga Malta Private Equity Health Strategist at Pictet Alternative Advisors. This episode is moderated by Hubertus Kuelps, Equity Partner at Pictet Group.
Podcast overview
- Assessing the Current State of Healthcare industry: Exploring how technology could serve as a solution to these problems and enhance the overall delivery of care.
- Cutting-Edge Health Innovations: Delving into the most promising areas of health technology, such as telemedicine, digital diagnostics, and genomics. Examining their potential to transform the healthcare industry for the better.
- Addressing Healthcare Challenges: Examining specific challenges in healthcare and how technology could be utilized to resolve these issues, including access to care, cost, and quality of care. By doing so, we shed light on the role technology could play in overcoming the obstacles faced by the healthcare industry.
Sangeeta Bhatia
Sangeeta is a cancer researcher, MIT professor and biotech entrepreneur who works to adapt technologies developed in the computer industry for medical innovation. Trained as both a physician and engineer at Harvard, MIT, and Brown University, Sangeeta Bhatia leverages 'tiny technologies' of miniaturization to yield inventions with new applications in tissue regeneration, stem cell differentiation, medical diagnostics, predictive toxicology and drug delivery. She and her trainees have launched more than 10 biotechnology companies to improve human health.
Lydia Haueter
Lydia joined Pictet Asset Management in 2016 and is a Senior Investment Manager in the Thematic Equities team. She also took on the Product Specialist function for Biotech and Health in 2019. Lydia began her investment career in 2011 at Bellevue Asset Management as part of the portfolio management team, where she was responsible for several portfolio holdings of BB Biotech AG. Lydia graduated 2011 with a Master of Science in Systems Biology from ETH Zürich with distinction, and she is a Chartered Financial Analyst (CFA) charter holder.
David Braga Malta
David is a Life Sciences Entrepreneur, Inventor and Investor. David is currently managing the health Private Equity fund of Group Pictet and previously, he was a Venture Partner of Vesalius Biocapital III. As an entrepreneur, David founded LiMM, Cell2B and BoostPharma. For his PhD, David worked at MIT on stem cell-based therapies at the Koch Institute. David developed high-throughput platforms for the study of cell and extracellular matrix interactions. His academic career focuses on the field of regenerative medicine with different publications and patents in the field.
Corporate Portraits at Pictet Geneva: Route des Acacias 60 - 1211 Geneva 73 - CH
